<DOC>
	<DOCNO>NCT00061620</DOCNO>
	<brief_summary>The goal clinical research study find high dose Tezacitabine ( FMdC ) safely give continuous infusion vein patient hematologic malignancy . The general safety effectiveness drug also study .</brief_summary>
	<brief_title>Phase I Study Continuous Infusion Schedule FMdC Hematologic Malignancies</brief_title>
	<detailed_description>Patients leukemias relapse previous therapy low cure rate . Hence need discover new antileukemic agent . Tezacitabine nucleoside analogue equivalent even superior activity compare ara-C leukemic cell line . It show significant antitumor activity vitro vivo tumor model . Several phase I study various dose schedule conduct solid tumor dose-limiting toxicity ( DLT ) mainly myelosuppression , usually favorable feature development leukemia . In phase I study hematological malignancy , use Tezacitabine bolus infusion daily x 5 . The DLT consist grade 3 CNS toxicity mucositis 3/6 patient . The study ongoing currently evaluate dose level 7.5 mg/m2 possible Maximum Tolerated Dose ( MTD ) . However , view fact tezacitabine cell cycle specific agent short terminal plasma half-life 2 6 hour , continuous infusion dose schedule may enhance activity reduce incidence adverse effect tezacitabine .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Tezacitabine</mesh_term>
	<criteria>Patient relapsed/refractory acute leukemia ( AML , ALL , highgrade myelodysplastic syndrome , CMML transformation &gt; /= 10 % peripheral blood/bone marrow blast , CML blast crisis ) , patient relapsed/refractory CLL absolute neutrophil count &gt; /= 1,000/ml platelet count &gt; /= 75,000/ml . Signed informed consent indicate patient aware investigational nature study , keep policy hospital . The acceptable consent form attach end protocol . Age &gt; /= 15 year . ECOG performance status &lt; /= 2 . No severe , concurrent disease , infection , comorbidity , judgment Investigator , would make patient inappropriate study entry . Pregnant and/or lactate female eligible . Normal organ function ( serum bilirubin £ 2 mg/dL , serum creatinine £ 2 mg/dL ) . Patients renal liver dysfunction due organ leukemic involvement may eligible discussion principle investigator . Patients must previous chemotherapy , immunotherapy , radiotherapy least 2 week prior enter study , must recover toxic effect , unless lifethreatening increase tumor burden occur .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Investigational</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Nucleoside analogue</keyword>
</DOC>